Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

Abstract

The authors evaluate the efficacy and safety of coadministered lanreotide Autogel (LA: 120 mg/month) and pegvisomant (40-120 mg/week) in acromegaly. In patients partially controlled by SSAs, LA (120 mg/months) plus pegvisomant normalized IGF1 in 57,9% of patients after 7 months, at a median effective pegvisomant dose of 60 mg/week, and 78,9% at any time.

In these patients, results suggest a pegvisomant-sparing effect versus daily pegvisomant monotherapy.

Keywords

• lanreotide Autogel
• pegvisomant
• IGF1 levels
• acromegaly
• somatostatin analogs